246 related articles for article (PubMed ID: 16373004)
1. Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?
Ribera E; López-Cortés LF; Soriano V; Casado JL; Mallolas J
Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():41-67. PubMed ID: 16373004
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefit of interventions driven by therapeutic drug monitoring.
Rendón A; Núñez M; Jiménez-Nácher I; González de Requena D; González-Lahoz J; Soriano V
HIV Med; 2005 Sep; 6(5):360-5. PubMed ID: 16156885
[TBL] [Abstract][Full Text] [Related]
3. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A
J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.
Justesen US
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):20-31. PubMed ID: 16433887
[TBL] [Abstract][Full Text] [Related]
8. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
Justesen US
Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
[TBL] [Abstract][Full Text] [Related]
9. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
Colombo S; Telenti A; Buclin T; Furrer H; Lee BL; Biollaz J; Decosterd LA;
Ther Drug Monit; 2006 Jun; 28(3):332-8. PubMed ID: 16778716
[TBL] [Abstract][Full Text] [Related]
10. An introduction to nucleoside and nucleotide analogues.
Squires KE
Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
[TBL] [Abstract][Full Text] [Related]
11. [Role of etravirine in combination antiretroviral therapy].
Domingo P
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
[TBL] [Abstract][Full Text] [Related]
12. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
13. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological considerations in antiretroviral therapy.
Sommadossi JP
Antivir Ther; 1998; 3 Suppl 4():9-12. PubMed ID: 10723503
[TBL] [Abstract][Full Text] [Related]
15. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
Joly V; Descamps D; Yeni P
AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
[TBL] [Abstract][Full Text] [Related]
16. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
Schoenenberger JA; Aragones AM; Cano SM; Puig T; Castello A; Gomez-Arbones X; Porcel JM
Ther Drug Monit; 2013 Feb; 35(1):71-7. PubMed ID: 23188184
[TBL] [Abstract][Full Text] [Related]
17. Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view.
Clevenbergh P; Mouly S; Sellier P; Badsi E; Cervoni J; Vincent V; Trout H; Bergmann JF
Curr HIV Res; 2004 Oct; 2(4):309-21. PubMed ID: 15544452
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of antiretroviral therapy.
Di Perri G; Sinicco A; Audagnotto S; Gobbi F; Canta F; Marrone R; Bonora S
New Microbiol; 2004 Apr; 27(2 Suppl 1):131-4. PubMed ID: 15646076
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
Introcaso CE; Hines JM; Kovarik CL
J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
